Mass Layoffs Expose Fragility of Danish Giant Amid Weight Loss Drug War
The leadership of Novo Nordisk, manufacturer of the weight loss medication Wegovy, announced on Wednesday (10) that it will lay off 9,000 people.
The layoffs are part of the company’s attempt to regain growth and defend itself against competition from the American Eli Lilly, as well as the pressure from generic drugs that are beginning to advance in the market.
According to the company, the restructuring is expected to generate savings of 8 billion Danish crowns (US$ 1.25 billion) per year, at a time when Novo Nordisk is facing a slowdown in its key obesity and diabetes medications.
-
Ypê puts R$ 130 million on the table after Anvisa identifies 88 sanitary failures, 142 batches with unsatisfactory analyses, and microbiological risk in a factory in SP; the company promises a “pharmaceutical level” laboratory and a task force to avoid another shutdown.
-
New Inmetro label removes D, E, and F refrigerators from shelves in Brazil since January: classes A, B, and C now pay up to R$ 400 less on the electricity bill.
-
CNH do Brasil sets record with 303% increase in the first four months of 2026: 4.8 million applied for their first driver’s license
-
Cold front advances to the South of Brazil this Sunday with up to 150 mm of rain and a new polar mass drops temperature in three states
From Global Champion with Wegovy to Billion-Dollar Loss: How Novo Nordisk’s Rise Turned into Free Fall
The company also issued its third profit warning of the year, citing 9 billion crowns in non-recurring costs related to the restructuring.
Nova Nordisk’s meteoric rise began in mid-2021, when Wegovy was approved in the United States as the first effective drug for obesity, catapulting the company to the top of the European stock market.
However, the wave of hiring that nearly doubled its workforce in five years has become a problem. Now, the cuts represent an attempt to “return to reality.”
Analyst Simon Baker from Redburn Atlantic was straightforward: “The mass layoffs bring Novo’s employee count back to levels seen at the beginning of 2024.”
Competition from Eli Lilly, Pressure from Generics and Billion-Dollar Cuts: Challenges That Could Define Novo Nordisk’s Future
The crisis did not stop with the cuts. In July, investors withdrew US$ 70 billion from the pharmaceutical company’s market value following a new profit alert and the appointment of veteran Mike Doustdar as CEO.
Since the beginning of the year, Novo Nordisk’s shares have already fallen nearly 46%, reducing its market capitalization to around US$ 181 billion — well below the peak of US$ 650 billion recorded last year.
In practice, this means that the company has lost approximately US$ 470 billion in market value in just over a year, a drop that has called into question its global leadership position.
The case of Novo Nordisk shows how success can turn into a crisis in just a few years. A company that once led the European market now faces tough cuts and increasingly impatient investors.
And you, do you believe that Novo Nordisk still has the stamina to reinvent itself with Wegovy, or will competitor Eli Lilly completely take the lead in this billion-dollar market?

-
-
4 people reacted to this.